Directors
Bruce Hundertmark
Chairman
Mr Hundertmark has extensive experience as an independent businessman across a broad range of industries. In recent years he has become involved in several health industry based companies both in Australia and internationally. He is presently a director of the biotechnology companies; Biotron Limited, Neubody Pty Ltd, PT Indo Bio Pertiwi, and PT Indobio Diversita Guna. The latter two companies are based in Indonesia and are searching for novel natural product based therapeutic agents.
Ines Atmosukarto
Managing Director/Chief Executive Officer
Dr Atmosukarto completed PhD studies in molecular biology at the University of Adelaide. She was a Research Scientist and Project Leader at the Indonesian Institute of Sciences (LIPI) and has been the CSO of an Indonesian drug discovery company.
Michael Hoy
Non-executive Director
Mr Hoy has more than 30 years corporate experience in Australia, the United Kingdom, USA and Asia. He is currently Chairman of the publicly listed biotechnology companies Biotron Ltd and Telesso Technologies Ltd and CityPrint Holdings Pty Ltd . He is a former director and Deputy CEO of John Fairfax Holdings Limited and the FXF Trust, and was an executive director of Times Newspapers Limited in London.
Professor Paul Rolan
Non-executive Director
Paul Rolan is the Professor of Clinical Pharmacology at The University of Adelaide and one of Australia's most experienced clinical pharmacologists with over 20 years experience in conducting Phase I clinical trials.
Boris Liberman
Non-executive Director
Mr Liberman is an experienced business man and investor whose family has built the large and diversified investment company JGL Investments Pty Ltd which has enjoyed sustained success in Australia for over 50 years.
Richard Bray
Non-executive Director and Company Secretary
Mr Bray is a Chartered Accountant (FCA) and a consultant of the Adelaide accounting firm Bray Chan Chartered Accountants. He is a director of Carrington Services Pty Ltd, the private equity consortium providing working capital to Lipotek.
